Free Trial

Pluri (PLUR) Competitors

Pluri logo
$5.05 +0.04 (+0.80%)
Closing price 07/16/2025 03:58 PM Eastern
Extended Trading
$5.05 0.00 (0.00%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PLUR vs. CYBN, VYGR, IMAB, ACOG, LFVN, DERM, IPHA, ENTA, SPRO, and NVCT

Should you be buying Pluri stock or one of its competitors? The main competitors of Pluri include Cybin (CYBN), Voyager Therapeutics (VYGR), I-Mab (IMAB), Alpha Cognition (ACOG), Lifevantage (LFVN), Journey Medical (DERM), Innate Pharma (IPHA), Enanta Pharmaceuticals (ENTA), Spero Therapeutics (SPRO), and Nuvectis Pharma (NVCT). These companies are all part of the "pharmaceutical products" industry.

Pluri vs. Its Competitors

Pluri (NASDAQ:PLUR) and Cybin (NYSE:CYBN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

16.6% of Pluri shares are held by institutional investors. Comparatively, 17.9% of Cybin shares are held by institutional investors. 25.9% of Pluri shares are held by company insiders. Comparatively, 15.0% of Cybin shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Pluri presently has a consensus target price of $12.00, indicating a potential upside of 137.62%. Cybin has a consensus target price of $85.00, indicating a potential upside of 1,030.32%. Given Cybin's stronger consensus rating and higher probable upside, analysts clearly believe Cybin is more favorable than Pluri.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pluri
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Cybin
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.25

In the previous week, Pluri and Pluri both had 1 articles in the media. Pluri's average media sentiment score of 0.93 beat Cybin's score of 0.52 indicating that Pluri is being referred to more favorably in the media.

Company Overall Sentiment
Pluri Positive
Cybin Positive

Pluri has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Comparatively, Cybin has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500.

Cybin has a net margin of 0.00% compared to Pluri's net margin of -2,563.29%. Cybin's return on equity of -37.58% beat Pluri's return on equity.

Company Net Margins Return on Equity Return on Assets
Pluri-2,563.29% -4,191.91% -85.40%
Cybin N/A -37.58%-36.59%

Pluri has higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pluri$330K120.43-$20.89M-$5.53-0.91
CybinN/AN/A-$57.88M-$3.88-1.94

Summary

Cybin beats Pluri on 9 of the 15 factors compared between the two stocks.

Get Pluri News Delivered to You Automatically

Sign up to receive the latest news and ratings for PLUR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PLUR vs. The Competition

MetricPluriMED IndustryMedical SectorNASDAQ Exchange
Market Cap$39.47M$2.90B$5.51B$9.31B
Dividend YieldN/A2.46%4.25%4.09%
P/E Ratio-0.9120.3628.1219.69
Price / Sales120.43298.74439.46100.25
Price / CashN/A42.3835.5357.53
Price / Book5.057.768.235.67
Net Income-$20.89M-$55.11M$3.23B$257.51M
7 Day Performance-6.65%0.19%-0.52%-0.16%
1 Month Performance19.10%10.80%6.71%9.89%
1 Year Performance-11.87%-0.68%27.10%15.08%

Pluri Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PLUR
Pluri
3.2867 of 5 stars
$5.05
+0.8%
$12.00
+137.6%
-13.7%$39.47M$330K-0.91150Positive News
Gap Down
CYBN
Cybin
2.5998 of 5 stars
$7.70
-2.2%
$86.00
+1,017.5%
N/A$176.13MN/A-1.7550
VYGR
Voyager Therapeutics
3.996 of 5 stars
$3.15
+3.6%
$13.39
+325.1%
-64.0%$173.82M$80M-2.15100News Coverage
IMAB
I-Mab
2.842 of 5 stars
$2.13
+1.7%
$6.00
+182.4%
+31.9%$173.53M$3.89M0.00380
ACOG
Alpha Cognition
1.733 of 5 stars
$10.75
-4.4%
$20.00
+86.0%
N/A$172.22MN/A-8.96N/A
LFVN
Lifevantage
4.2344 of 5 stars
$13.43
-1.2%
$30.50
+127.1%
+97.8%$169.02M$200.16M19.46260News Coverage
Positive News
DERM
Journey Medical
2.4054 of 5 stars
$7.23
+1.8%
$9.50
+31.4%
+21.8%$165.55M$56.13M-18.2290
IPHA
Innate Pharma
2.5992 of 5 stars
$1.79
-1.6%
$11.00
+514.5%
-16.3%$165.00M$21.77M0.00220
ENTA
Enanta Pharmaceuticals
3.755 of 5 stars
$7.77
-1.5%
$18.00
+131.7%
-56.1%$164.26M$67.64M-1.69160News Coverage
SPRO
Spero Therapeutics
3.9219 of 5 stars
$2.94
+1.2%
$5.00
+70.4%
+64.7%$164.10M$47.98M-2.29150
NVCT
Nuvectis Pharma
3.3079 of 5 stars
$7.82
-0.4%
$17.00
+117.5%
+18.4%$163.36MN/A-6.928Positive News

Related Companies and Tools


This page (NASDAQ:PLUR) was last updated on 7/17/2025 by MarketBeat.com Staff
From Our Partners